Trade Names:Phospholine Iodide- Powder for reconstitution 6.25 mg to make 0.125%
Causes miosis, increase in facility of outflow of aqueous humor, fall in IOP, and potentiation of accommodation by enhancing the effect of endogenously liberated acetylcholine in the iris, ciliary muscle, and other parasympathetic innervated structures of the eye.
Treatment of chronic open-angle glaucoma; treatment of accommodative esotropia.
Active uveal inflammation; most cases of angle-closure glaucoma because of the possibility of increasing angle block; hypersensitivity to any component of the product.
Ophthalmic Use the lowest concentration that will control the IOP around-the-clock. Two doses a day are preferred to one in order to maintain as smooth a diurnal tension curve as possible.Early chronic simple glaucoma
Instill 0.03% twice daily, just before bedtime and in the morning.Advanced chronic simple glaucoma and glaucoma secondary to cataract surgery
Instill 0.03% twice daily. When transferring to echothiophate because of unsatisfactory control with one of the other agents, one of the higher strengths of echothiophate iodide may be needed. In this case, a brief trial with 0.03% may be advantageous in that the higher strengths then will be more easily tolerated.Accommodative EsotropiaChildren
Ophthalmic Diagnosis: Instill 1 drop of 0.125% once daily in both eyes on retiring, for 2 to 3 wk. If esotropia is accommodative, a favorable response will usually be noted within a few hours. Treatment: Use the lowest concentration and frequency that gives satisfactory results. After initial period for diagnostic purposes, the schedule may be reduced to 0.125% every other day or 0.06% every day. Often the dosage can be gradually reduced as treatment progresses.
Store unopened bottles with powder for reconstitution in refrigerator (36° to 46°F). Reconstituted eye drops may be stored at controlled room temperature (77°F) for up to 4 wk. Discard any unused solution after 4 wk.
The effects of these agents may be potentiated by echothiophate.
None well documented.
Activation of latent iritis or uveitis; brow ache; burning; conjunctival and ciliary redness; conjunctival thickening; induced myopia with visual blurring; iris cysts, which may obscure vision; lacrimation; lens opacities; lid muscle twitching; obstruction of nasolacrimal canals; paradoxical increases in IOP; retinal detachment; stinging.
Ensure IOPs are measured and documented in the patient's record before starting therapy and periodically thereafter. Inform health care provider of abnormal pressures. Be prepared to change therapy if IOPs are not controlled with echothiophate iodide.Adverse reactions
Monitor patient for development of cardiac arrhythmias, excessive salivation, urinary incontinence, diarrhea, profuse sweating, muscle weakness, or respiratory difficulties. Inform health care provider if noted. Be prepared to temporarily discontinue medication.
Category C .
Because of potentially serious adverse reactions in breast-feeding infants, decide whether to discontinue breast-feeding or the drug.
Use with extreme caution, if at all, in patients with a history of retinal detachment or in patients with marked vagotonia, bronchial asthma, spastic GI disturbances, peptic ulcer, pronounced bradycardia and hypotension, recent MI, epilepsy, parkinsonism, and other disorders that may respond adversely to vagotonic effects. Temporarily discontinue if salivation, urinary incontinence, diarrhea, profuse sweating, muscle weakness, or respiratory difficulties occur.
Routine examination to detect lens opacity should accompany use of echothiophate.
Avoid use or use with caution in patients with quiescent uveitis or a history of this condition because of the possibility of intense and persistent miosis and ciliary muscle contraction.
Copyright © 2009 Wolters Kluwer Health.